HISUN(SH:600267) Cai Jing Wang·2025-10-28 10:00Core Viewpoint - Recently, Haizheng Pharmaceutical announced its Q3 2025 financial results, showing mixed performance with slight revenue growth but a decline in net profit [1] Financial Performance Summary - For the first three quarters of 2025, the company's operating revenue reached 7.92 billion yuan, an increase of 0.6% year-on-year [1] - The net profit attributable to shareholders was 461 million yuan, a decrease of 10.6% year-on-year [1] - The net profit excluding non-recurring items was 491 million yuan, reflecting a significant increase of 42.0% year-on-year [1] - The net cash flow from operating activities was 1.645 billion yuan, up 13.0% year-on-year [1] - The earnings per share (EPS) on a fully diluted basis was 0.3845 yuan [1] Q3 Performance Summary - In Q3 2025, the company's operating revenue was 2.67 billion yuan, showing a year-on-year increase of 1.6% [1] - The net profit attributable to shareholders for Q3 was 162 million yuan, marking a substantial increase of 102.1% year-on-year [1] - The net profit excluding non-recurring items for Q3 was 169 million yuan, up 96.1% year-on-year [1] - The EPS for Q3 was 0.135 yuan [1] Shareholder Initiatives - The company is currently conducting a share buyback to support its employee stock ownership plan [1]